Tag: 5-HT₂C receptor agonist

This 2013 review evaluates lorcaserin, a selective 5-HT₂C receptor agonist, for chronic weight management in obese and overweight adults. Clinical trials demonstrated that lorcaserin, as an adjunct to diet and exercise, led to significant weight loss compared to placebo. After 12 months, a higher proportion of lorcaserin-treated patients achieved ≥5%